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Purpose: Histone citrullination by peptidylarginine deiminases 4 (PAD4) regulates the gene 
expression of tumor suppressor. In our previously study, YW3-56 (356) was developed as 
a potent PAD4 inhibitor for cancer therapy with novel function in the autophagy pathway. To 
enhance the antitumor activity, the PAD4 inhibitor 356 was modified by the well-established 
cationic penetrating peptide RKKRRQRRR (peptide TAT) and gold nanoparticles to obtain 
356-TAT-AuNPs which could enhance the permeability of chemical drug in solid tumor.
Methods: 356-TAT-AuNPs were prepared, and their morphology were characterized. The 
antitumor activity of 356-TAT-AuNPs was evaluated in vitro and in vivo.
Results: 356-TAT-AuNPs exhibited higher anticancer activity against HCT-116, MCF-7 and 
A549 cells than 356 and 356-AuNPs. Compared with 356 and 356-AuNPs, 356-TAT-AuNPs 
entered the cytoplasm and nuclear, exhibited stronger anticancer activity by increasing 
apoptosis, inducing autophagy and inhibiting of histone H3 citrullination, and in HCT-116 
xenograft mouse model, 356-TAT-AuNPs could improve the antitumor activity.
Conclusion: The modified AuNPs with peptide TAT as drug delivery system are potent in 
delaying tumor growth and could be a powerful vehicle for profitable anticancer drug 
development. We believe that peptide TAT modification strategy may provide a simple and 
valuable method for improving antitumor activity of PAD4 inhibitors for clinical use.
Keywords: Au nanoparticle, transmembrane peptide, PAD4 inhibitor, antitumor
Introduction
PADs are a family of calcium dependent enzymes that could post-translationally 
convert Arginine (Arg) residues with positive charges to neutrally charged 
Citrulline.1 PAD-mediated citrullination could alter the tertiary structure of target 
peptide and/or the protein-protein interactions, thereby modifying various cellular 
processes.2 Recently, protein citrullination (Cit) has received increased attention due 
to its functions in various human cancers as well as its implication in the pathogenesis 
of different inflammatory conditions.3 This type of protein or peptide modification was 
first explored in autoimmune disorder, such as rheumatoid arthritis.4 Among this Cit 
process catalyzed by the PADs family, the well-known histone Cit provides the 
important mechanism for neutrophil extracellular traps (NETs) in the peripheral 
blood.5 Further explorations revealed that Cit of proteins or peptides is also involved 
in carcinogenesis process. Citrullinated proteins or peptides disturbed the structure 
stability, and induced DNA damages. More and more studies show that citrullinated 
proteins or peptides can be applied as promoting targets for diagnosis or treatment of 
cancer.6 The PAD4 inhibitor, YW3-56 (356), could effectively inhibit cancer growth 
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in sarcoma S-180 bearing mouse model,7 but water solubi-
lity of free 356 is rather poor.
In this study, we designed Au nanoparticles (Au-NPs) as 
drug delivery systems for compound 356 to increase the 
antitumor activity on gastrointestinal cancer cells and 
improve its solubility (as shown in Figure 1). Recently, 
functionalized Au-NPs system represents highly appealing 
and promising options for drug controlled releasing and drug 
delivery, owing to the special dimensions and tunable func-
tionalities of Au-NPs’ surface, especially.8–10 Peptide TAT, 
derived from HIV and discovered as the first cell-penetrating 
peptide (CPP), has been widely designed to decorate drug 
delivery systems and bio-functional molecules.11–13 Here we 
report the design of gold nanoparticles modified by TAT to 
improve the transmission to the nucleus and kill cancer cells.
Materials and Methods
Materials
Chemistry. General Methods. Silica gel thin-layer chroma-
tography (TLC) separations were performed on GF-254 
plates (Qingdao Haiyang Chemical, China). All organic 
solvents and reagents were analytically pure with no 
further purification. All starting materials in the synthesis 
were commercially available.1H NMR and 13C NMR spec-
tra were performed and recorded on AVANCE 300 spec-
trometers (Bruker Company, Germany) using DMSO-d6 
as the solvent and TMS as the internal standard.
Gold chloride trihydrate and Dimethyl sulfoxide were 
purchased from Aladdin Biochemical Technology 
(Shanghai, China). PI detection kits were purchased from 
Solarbio Science &Technology (Beijing, China). 
Phalloidin FITC Reagent, Anti-Histone H3 citrulline R2 
antibody, IgG H&L (Alexa Fluor® 568), PADI4 Rabbit 
Polyclonal antibody, LC3 antibody, and anti-β-actin pri-
mary antibody were provided from Abcam (USA).
Preparation of compound 356: According to the 
literature,7 compound 356 was synthesized (Figure S3), sep-
erated and purified by flash chromatography (200–400 mesh 
silica gel; 5% MeOH/DCM as eluent) to give compound 356 
as pale yellow solid. Yield: 47 mg (24% in 5 steps). 
Compound 356 was further purified using a Waters HPLC 
system with a reverse phase C18 column (XBridge Peptide 
BEH C18 OBD 5 μm, eluted by 70%ACN/30%H2O with 
0.1%TFA). 1H NMR (300 MHz, DMSO-d6, δ): 10.25 (s, 
1H, H+), 9.61 (s, 1H, =NH), 9.21 (s, 1H, NH), 8.82 (d, J = 9 
Hz, 1H; CONH), 8.67 (t, J = 6 Hz, 1H; CONH), 8.25 (s, 1H; 
Ar H), 7.94 (d, J = 6 Hz, 1H; Ar H), 7.85 (d, J = 6 Hz, 1H; 
Figure 1 Schematic representation of the 356-TAT-AuNPs formation and delivery system.
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Ar H), 7.78 (d, J = 6 Hz, 2H; Ar H), 7.60–7.39 (m, 4H; Ar 
H), 7.33–7.22 (m, 4H; Ar H), 4.57 (m, 1H; CH), 4.44 (s, 2H; 
CH2Cl), 4.31 (d, J = 3 Hz, 2H; CH2C6H5), 3.35 (s, 6H; 
C(CH3)2), 3.32 (m, 2H; NCH2), 1.88 (m, 2H; CH2), 1.66 (m, 
2H; CH2); MS C27H32ClN5O2 [M+H]+: 494.4. And the 
spectra were supplied and described in detail in Figure S4– 
S6 of the Supporting Information.
Preparation of 356-TAT-AuNPs: Au-NPs (17 nm) was 
prepared by the classical sodium citrate reduction method 
of HAuCl4 in aqueous phase. The aqueous solution 
(100 mL, 0.23 mM) of tetrachloroacid trihydrate is heated 
and refluxed and stirred. When it is boiling, sodium citrate 
aqueous solution (1%, 5 mL) is quickly added, mixed and 
stirred for 10 mins, and cooled to room temperature (rt). 
The product whose color changes to bright red is colloidal 
solution of gold nanoparticles. Then in order to obtain 
356-AuNPs, add the fresh 356 solution (1.5 mL, 0.2 mg/ 
mL, DMSO) to the above prepared colloidal solution of 
gold nanoparticles, stirring for 3 hours at rt to obtain 356- 
AuNPs; in order to prepare 356-TAT-AuNPs, TAT solution 
(20 μL, 0.1 mm, H2O) was added to the freshly prepared 
100 mL solution of gold nanoparticles, stirring for 1 min, 
and then 1.5 mL 356 solution (0.2 mg/mL, DMSO) was 
added and stirred at rt for 3 hours to obtain 356-TAT- 
AuNPs. The prepared sample solutions were sealed over-
night in 4 °C, and then the raw materials were removed by 
centrifugation (8000 rpm, 10 mins), washed and purified 
with ultrapure water. The precipitates were redistributed in 
5 mL of the mixture (DMSO and water, 0.5:99.5).
Nanoparticle Formation and 
Concentration Determination
The formation of AuNPs in ultrapure water was measured 
and recorded by UV-vis spectroscopy on a UV-2550 spec-
trometer (Shimadzu, Kyoto, Japan) ranged from 200 to 
800 nm). A series of concentrations (2.0, 5.0, 10.0, 15.0, 
20.0, 25.0 and 30.0 µg/mL) of compound 356 were 
detected by UV-Vis. The absorbance value of compound 
356 was set as the y axis in the standard curve, while the 
concentration of compound 356 was set as the x axis. By 
using the weighted least-square method, linear regression 
analysis was then performed. The concentration of 356 in 
AuNPs was also measured by UV-vis.
Nanoparticle Characterization
The morphology and characterization of the AuNPs were 
measured by transmission electron microscopy (JEOL, 
2100, Japan). The average size and zeta potential of 
Nanoparticles were detected by a Zetasizer Nano instru-
ment (Malvern, UK). Before dynamic light scattering 
(DLS) characterization, the AuNPs were diluted in H2 
O to 1 mg/mL, the AuNPs in ultrapure water was passed 
through 0.45 μm polyvinylidene fluoride membrane. The 
sample was loaded into quartz microcuvette. For each 
nanoparticle system, data obtained from three detections 
were averaged to calculate the mean zeta potential and 
size.
Cell Culture and Cell Viability
Human HCT-116 cells (colorectal carcinoma), human 
MCF-7 cells (breast cancer) and human A549 cell lines 
(non-small-cell lung carcinoma) were obtained from 
American Type Culture Collection (ATCC). HCT-116 
and A549 cells were maintained in RPMI 1640 Medium 
(Gibco by Life Technologies) with 10% fetal bovine serum 
(FBS). MCF-7 cells were maintained in DMEM (Gibco by 
Life Technologies) with 10% FBS.
Cell viability treated with different samples was 
detected by MTT assays. Briefly, 3×103 HCT-116, MCF- 
7 and A549 cells were plated in 96-well plates. After 6 h, 
the medium was removed and the fresh culture medium 
containing designed concentrations of AuNPs, 356, 356- 
AuNPs and 356-TAT-AuNPs. After another 24 h, 25 µL of 
5 mg/mL MTT solution was added to the 96-well plate, 
and the cells were cultured for another 4 h. 100 µL of 
DMSO was then added to dissolve the purple formazan 
crystals, and the OD value (492 nm) was detected with 
a microplate reader (MiniMax 300 Imaging Cytometer, 
Molecular Devices, USA).
Laser Confocal Microscopy Analysis
The cellular internalization and distributions were 
observed by confocal microscopy: HCT-116 cells were 
cultured for 24 h until total adhered on glass-bottom 
dishes. The cells were then incubated with 356, 356- 
AuNPs and 356-TAT-AuNPs dissolved in media 
(Maintain 356 concentration of 5 μM in RPMI 1640 med-
ium) at 37°C for 12 h. Washed with cold PBS three times, 
the cells were treated with FITC Phalloidin (100 nM) and 
PI (20 μg/mL) to stain the nucleus and cytoskeleton. Then 
the cells were characterized immediately and analyzed 
using a laser scanning confocal microscope (Leica, TCS 
SP8, Germany). The excitation wavelength and detection 
wavelength of 356, FITC Phalloidin and PI were 403 and 
462 nm, 488 and 530 nm, 535 and 618 nm, respectively.
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In vitro Immunofluorescent Staining
Confocal microscopy was used to investigate the effects 
on Histone H3 Citrullination. Briefly, HCT-116 cells were 
cultured for 24 h until total adhered on glass-bottom 
dishes. Then 356, 356-AuNPs and 356-TAT-AuNPs dis-
solved in media (Maintain 356 concentration of 5 μM in 
RPMI 1640 medium) were added into the cells and incu-
bated at 37°C for 12 h. Washed with cold PBS three times, 
0.1% Triton x-100 was then added to increase the cell 
permeability; 5% goat serum was added and blocked at 
rt for 2 h. After washing with PBS, Rabbit Anti-Histone 
H3 antibody was added and treated at 4 °C for 15 h. After 
washing thrice with PBS, goat anti-rabbit IgG H&L 
(Alexa Fluor® 568) was added, and it was treated in 
a dark box at rt for 1 h. After PBS washing, FITC was 
added to treated for 45 min. The excitation and emission 
wavelengths of 356, FITC and Alexa Fluor 568 were 403/ 
462 nm, 488/530 nm, and 578/603 nm, respectively. And 
the confocal fluorescence images were obtained via con-
focal laser scanning microscope (CLSM, TCS SP8 STED, 
Germany).
Apoptosis
Propidium iodide (PI) and Annexin V-FITC stainings were 
used to characterize the apoptosis of HCT-116 cells treated 
with 5 μM of 356, 356-AuNPs and 356-TAT-AuNPs 
diluted in culture medium for another 12 h and 
24 h. Control groups were cultured in medium (with 
10% FBS). The cells were resuspended in 500 μL of 
binding buffer (0.14 M NaCl and 2.5 mM CaCl2, 10 nM 
HEPES, pH 7.5) containing 5 μL of PI and 5 μL of 
Annexin V-FITC for 30 min at rt in the dark, and then 
the fluorescence intensity was measured on a flow cyt-
ometer (Becton Dickinson FACS Calibur, USA).
Subcellular Ultrastructure and 
Localization by TEM
The TEM analysis was used to investigate the intracel-
lular localization of 356-TAT-AuNPs inside the HCT- 
116 cells. The cells were seeded in 24-well plates with 
plastic cover slips at a density of 1×106 cells/well and 
cultured. After 24 h, the cells were exposed to 356 
(5 μM), 356-AuNPs (5 μM), 356-TAT-AuNPs (5 μM) 
for further 24 h. Then cells were washed three times 
with PBS, and fixed by 2.5% glutaraldehyde in 100 mM 
sodium cacodylate buffer for 4 h at 4°C. Then HCT-116 
cells were post-fixed in 1% OsO4 aqueous solution and 
embedded into epoxy resin later. Thin sections (50~70 
nm) were harvested. The ultrastructure were character-
ized by TEM (JEOL, 2100, Japan).
Cell Uptake by Inductively Coupled 
Plasma Optical Emission Spectrometer 
(ICP-OES)
To measure the intracellular uptake of the AuNPs, 356- 
AuNPs and 356-TAT-AuNPs in HCT-116 cells, cells 
were grown in 24-well culture plates (5×104 cells in 
1 mL of the medium per well). After incubation for 
24 h at 37°C, the cells were incubated with AuNPs, 
356-AuNPs and 356-TAT-AuNPs (Maintain 356 concen-
tration of 5 μM in RPMI 1640 medium) for 4 hand 
24 h. After washing three times by PBS, AuNPs were 
digested in 1 mL of aqua regia solution. Then each 
sample solution volume was made up to 10 mL in 
a volumetric flask with distilled water, and the content 
of Au was measured by ICP-OES.
Western Blotting
Incubated with 5 μM AuNPs, 356, 356-AuNPs and 356-TAT- 
AuNPs for 8 h, the HCT-116 cells were harvested on ice and 
lysed. After centrifugation the precipitates were collected, and 
by using the kit (bicinchoninic acid-protein assay), the total 
concentration of protein was detected. A total of 20 μg of 
protein were purified by 10% sodium dodecyl sulphate- 
polyacrylamide (SDS-PAA) gel and then the protein was 
transferred to nitrocellulose membranes (Millipore, USA). 
Followed by blocking with 5% nonfat milk, the membranes 
were incubated with a rabbit anti-PADI4 Rabbit Polyclonal 
antibody (dilution 1:1000), rabbit anti-LC3 antibody (dilution 
1:1000), or a mouse anti-β-actin monoclonal antibody (dilu-
tion 1:2000). The membranes were then incubated with the 
goat anti-mouse or goat anti-rabbit horseradish peroxidase 
(HRP) secondary antibody (Sigma, USA). And the protein 
complex was measured using the enhanced chemilumines-
cence reagent (Millipore, USA). β-actin was the internal 
control.
The Therapeutic Efficacy in vivo
The old male BALB/c nude mice (3 to 5-week) were 
supplied by Charles River Laboratories, and all experi-
mental protocols and procedures were approved by the 
Institutional Animal Care and Use Committee of Capital 
Medical University (the Ethics Number AEEI-2018-174). 
Laboratory animal welfare (PR China National Standard 
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GB/T 35,892–2018) was given in animal studies. HCT- 
116 cells of 2×106 prepared from 4 tumor bearing mice 
were xenografted subcutaneously at right flank of the 
mice. Tumor diameters were detected every other day 
by a Vernier caliper. The mice were randomly divided 
into 4 groups (normal saline (NS), AuNPs, 356 and 356- 
TAT-AuNPs) and treated by drugs when the average 
volume of tumor reached ~100 mm3. 356 and 356-TAT- 
AuNPs were administered (i.p.) twice per week for 6 
times altogether. And the samples were prepared and 
redistributed in the mixture of DMSO and water 
(0.5:99.5, 5 mL) as same as above in the section of 
Preparation of 356-TAT-AuNPs. The mice body weights 
were weighed every other day. Tumor volume (V) was 
then calculated by the following formula: V = a2b/2 
(where a and b represent the shortest and the longest 
diameter, respectively of the tumor).
Statistical Analysis
All the experiments and bioassays in this study were con-
ducted at least 3 times. Quantitative data were expressed 
as the mean ± standard deviation. Statistical differences 
were represented using the GraphPad Prism 7.0 (GraphPad 
Software, CA). Comparisons between the control and 
treated groups were performed by One-way and the two- 
way ANOVA. A p value of less than 0.05 was recognized 
as statistically significant.
Results
Synthesis of Free 356-Loaded Au 
Nanoparticles 356-AuNPs and 356-TAT- 
AuNPs
The UV-vis spectra profile of 356-AuNPs and 356-TAT- 
AuNPs was characterized (Figure S1A). It was determined 
that compound 356 had a Amax (maximum absorption wave-
length) of 328 nm at different concentrations. Therefore, 
Amax (328 nm) was set as the wavelength for compound 
356’s concentration detection. The regression equation was 
calculated to be y = 0.0326x - 0.0382, with R2 = 0.9995 
(Figure S1B). The absorption spectrum of AuNPs is mea-
sured in water, and the absorption peak is at 520 nm. Upon 
being loaded with 356 and TAT on AuNPs, the large absorp-
tion band in 356-AuNPs and 356-TAT-AuNPs shifted from 
520 to 560 nm. 356-AuNPs and 356-TAT-AuNPs are nega-
tively charged with mean surface charge of −28.70 ± 4.03 
mV and −15.15 ± 0.12 mV, respectively (Table S1).
Au nanoparticles (AuNPs) with a diameter of 16.45 ± 
0.82 nm (Figure 2A) were prepared by the classical sodium 
citrate reduction method of HAuCl4 and characterized at 
neutral pH by transmission electron microscopy (TEM).14 
356-AuNPs were prepared by adding a fresh free 356 solu-
tion to the above colloidal system. The 356-AuNPs exhibit 
a relatively narrow size distribution and the average size is 
16.60 ± 1.31 nm based on the TEM image (Figure 2B). To 
Figure 2 Transmission electron microscopic (TEM) image and size distribution of AuNPs (A1 and A2), 356-AuNPs (B1 and B2) and 356-TAT-AuNPs nm (C1 and C2).
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improve the antitumor efficacy, cell-penetrating peptide TAT 
was used to prepare 356-TAT-AuNPs with a diameter of 
16.78 ± 1.48 nm (Figure 2C). The 356-AuNPs and 356- 
TAT-AuNPs are not stable at pH = 5.5 (data not shown). 
However, at pH = 6.5, 356-AuNPs and 356-TAT-AuNPs are 
stable with the average diameter of 50 nm and polydisperse 
index (PDI) of 0.223 measured by DLS as shown in Table 
S1 on the 7th day at rt. Since DLS measures the hydrated 
particle size, the particle size characterized by DLS is higher 
than the result characterized by TEM.
In vitro Antitumor Activity
To evaluate cell-penetrating peptide TAT and AuNPs 
that could improve the anticancer efficacy of free 356, 
the cell viability of HCT-116, A549 and MCF-7 cells 
was determined by MTT method. The result of cell 
viability shows that AuNPs and TAT-AuNPs exhibited 
no toxicity in tumor cells (Figure S2) with above 90% 
viability even at the high concentration of 400 μg/mL. 
As shown in Figure 3A–C, after being loaded with 
AuNPs and TAT, 356-AuNPs and 356-TAT-AuNPs 
exhibited low toxicity in MCF-7 and A549 cells, but 
decreased the viability of HCT-116 cells significantly. 
Moreover, 356-TAT-AuNPs induced stronger inhibition 
compared with free 356 and 356-AuNPs, it indicated 
that TAT modified gold nanoparticles could enhance 
free 356 antitumor activity in vitro. And the cell viabi-
lity in Figure 3D shows that along with the increasing 
concentrations 356-TAT-AuNPs decreased the viability 
of HCT-116 cells significantly, while in contrast, it 
declined slowly on MCF-7 and A549 cells, indicating 
that the HCT-116 was more sensitive. On the basis of 
the cell viability results, HCT-116 cell line was selected 
for the subsequent experiments.
Apoptosis Analysis by Flow Cytometry
To explore the apoptosis inducing capability of free 356, 
356-AuNPs and 356-TAT-AuNPs, the apoptosis assay 
was performed by FACS analysis (staining with PI and 
Annexin V FITC) in HCT-116 cells. As seen in Figure 
4, after incubation with 5 μM free 356 for 12 h, only 
<10% of apoptotic cells were observed, while compared 
with free 356 and 356-AuNPs, 356-TAT-AuNPs induced 
a fairly large increase in cell apoptosis at the same 
concentration. After 24 h of treatment with 356-TAT- 
AuNPs, up to 42.3% of cancer cells underwent either 
Figure 3 The in vitro cytotoxicity of free 356, 356-AuNPs and 356-TAT-AuNPs against HCT-116 (A), MCF-7 (B) and A549 (C) after 24h incubation, and in vitro cytotoxicity 
of 356-TAT-AuNPs against HCT-116, MCF-7 and A549 cells (D). Data represent the mean ± SD (n =6).
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early apoptosis or late apoptosis. 356-TAT-AuNPs 
exhibited a stronger apoptotic effect than free 356 and 
356-AuNPs. These results suggest that TAT modified 
gold nanoparticles could enhance free 356 antiapoptotic 
activity in vitro.
Cellular Uptake and Intracellular 
Distribution
In order to explore that whether TAT and AuNPs could 
assist in transferring free 356 into cytoplasm, the coloca-
lization and cellular uptake of 356-TAT-AuNPs were 
determined using CLSM analyses using the fluorescent 
signal of the naphthalene group in free 356. As shown in 
Figure 5A, faint blue fluorescence of 356 was measured 
in the cells with treatment of 356, and the result implied 
that free 365 was not easy to penetrate through cell 
membranes to be taken up. However, the bright blue 
fluorescence was observed in 356-AuNPs and 356-TAT- 
AuNPs group, these figures indicated that 356-TAT- 
AuNPs entered HCT-116 cells effectively, and the blue 
fluorescence of free 356 in the 356-AuNPs and 356-TAT- 
AuNPs distributed all over the HCT116 cells, and pri-
marily in the nuclei.
The cellular uptake of Au was quantified after 
4 h and 24 h incubation with AuNPs, 356-AuNPs and 
Figure 4 Effects of free 356, 356-AuNPs and 356-TAT-AuNPs to induce apoptosis of HCT-116 cells. (A) HCT-116 cells were treated with 5 μM compounds for 12 h and 24 
h. The apoptosis rate was measured using flow cytometry. (B) The percentage of cells in each population for 12 h. (C) The percentage of cells in each population for 24 
h. Data represent the mean ± SD (n =3). **p < 0.01 vs control; #p < 0.05, ##p < 0.01.
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356-TAT-AuNPs by ICP-OES measurement. As shown 
in Figure 5B, higher mass amounts of Au was taken up 
after incubation with 356-TAT-AuNPs compared to 356- 
AuNPs in 4 h. Amounts of Au showed a significant 
increase in uptake after 356-AuNPs treatments of 
4 h and 24 h (1.9-fold). For the 356-TAT-AuNPs this 
resulted in a 2.8-fold higher cellular Au amount. 
Furthermore, amounts of Au treated with 356-TAT- 
AuNPs were 3.1-fold higher than the 356-AuNPs treated 
group after incubation with 24 h. Therefore, 356-TAT- 
AuNPs can penetrate into cells more efficiently. 356- 
TAT-AuNPs exhibited a stronger anti-cell proliferation 
Figure 5 Cellular uptake and intracellular distribution. (A) Confocal laser scanning microscope images of HCT-116 cells incubated with 356 (5 μM), 356-AuNPs (5 μM), 356- 
TAT-AuNPs (5 μM) for 12 h. The cells were treated with PI (20 μg/mL, EM 618 nm; EX 535 nm) and FITC phalloidin (100 nM, EM 530 nm; EX 488 nm) at rt to stain the 
nuclei and cytoskeletons.356 was excited at the wavelength of 403 nm, and the fluorescence images were recorded at emission wavelengths of 462 nm. Scale bar: 10 μm. (B) 
The cellular uptake of AuNPs, 356-AuNPs and 356-TAT-AuNPs quantified by ICP-OES with HCT-116 cells. Data represent the mean ± SD (n =3) vs 356-AuNPs, **p < 0.01.
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and apoptotic effect than 356-AuNPs, which may due to 
the increased uptake rate.
Inhibition of Histone H3 Citrullination
Citrullinated Histone H3 (H3Cit) is an posttranslational and 
irreversible modification of Arg residues in peptides or 
proteins, and considered a neutrophil extracellular traps 
(NET)-specific biomarker.15 To further demonstrate the 
role of 356 in cell killing, H3Cit (Figure 6) was detected. 
The amount of histone H3 citrullination was analyzed using 
anti-histone H3 Cit 2 antibody (Abcam). The staining 
revealed strong nuclear labeling in the HCT-116 cell line 
treated with DMSO, which was less diffuse in the groups of 
free 356 and 356-TAT-AuNPs. Notably, 356-TAT-AuNPs 
was able to inhibit the H3Cit formation significantly. 
Meanwhile, the brighter blue fluorescence was observed in 
356-TAT-AuNPs group as shown in Figure 6, which was 
consistent with the previous results. The results showed that 
free 356 can significantly increase the inhibition of H3Cit 
activity by means of modification with TAT and AuNPs.
AuNPs Could Enhance the 356 Releasing 
and Induce Autophagy in HCT-116 Cells
As showed in Figure 7A, a few nanoparticles were detected 
in the nucleus, mitochondria and autolysosome based on the 
TEM images of treating with 356-TAT-AuNPs for 24 h, 
perhaps suggested that peptide TAT on the surface of 
AuNPs facilitated either rapid escape from the endocytic 
system, or translocation of plasma membrane, or both. 
Based on the CLSM images and TEM images, the nanopar-
ticles were distributed into cytosol and nucleus initially. 
After 24 h, nanoparticles become reversibly associated 
with endolysosomal vesicular system, especially the auto-
lysosome, perhaps by a novel trafficking pathway.
Western Blot Analysis of Protein 
Expression in vitro
The formation of autophagosomes and phagophores related 
to the lipidation of LC3-I to yield the LC3-II protein.16 To 
investigate whether 356-TAT-AuNPs treatment regulates 
Figure 6 Confocal laser scanning microscope images of HCT-116 cells incubated with 356 (10 μM), 356-AuNPs (10 μM), 356-TAT-AuNPs (10 μM) for 12 h. The cells were 
treated with anti-Histone H3 antibody and FITC phalloidin (100 nM, EM 512–558 nm; EX 488 nm) to mark the Histone H3 and stain cytoskeletons.356 was excited at the 
wavelength of 403 nm, and the fluorescence images were recorded at emission wavelengths of 462 nm. Scale bar: 10 μm.
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autophagy in HCT-116 cells, levels of LC3-II and LC3-I 
were analyzed by Western blotting after 356-TAT-AuNPs 
treatment for 8 h. LC3-II protein accumulated after 356, 356- 
AuNPs and 356-TAT-AuNPs treatment (Figure 7B), which is 
consistent with the autophagic vesicle accumulation. We 
found that dramatically more LC3-II accumulated in 356- 
TAT-AuNPs treated cells than 356 and 356-AuNPs treated 
cells, suggesting that 356-TAT-AuNPs inhibited autophagic 
vesicle breakdown by the lysosome.
As reported above, 356-TAT-AuNPs treatment 
decreased histone H3 citrullination by the confocal micro-
scopy analysis (Figure 6), we further tested the levels of 
PAD4 by Western blotting. The results (Figure 7B) indi-
cated that the expression of PAD4 decreased significantly 
Figure 7 356-TAT-AuNPs induces autophagy in HCT-116 cells. (A) Transmission electron microscopy (TEM) images of HCT-116 cells treated with 356 (5 μM), 356-AuNPs 
(5 μM), 356-TAT-AuNPs (5 μM) for 24 h. Scale bar: 5 μm, low magnification (low mag.); 1 μm, high magnification (high mag). (B) Effects of AuNPs, 356, 356-AuNPs, 356-TAT- 
AuNPs on protein expression of HCT-116 cancer cells. Western blot analysis of proteins (PADI4 and LC3) as indicated in HCT-116 cancer cells treated with the indicated 
compounds for 8 h. β-actin was used as a loading control.
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after treated with 356-TAT-AuNPs, which was consistent 
with the previous result.
Antitumor Efficacy in vivo
To test the effect of 356-TAT-AuNPs on tumor growth, 
a well-established HCT-116 cell-derived tumor bearing 
mice model was used.17 After intraperitoneal injection of 
356 with dose of 10 μmol/kg twice a week (BIW) for three 
weeks, the HCT-116 tumor growth was decreased to 51.6% 
comparing to the tumor size of the NS group. By conjugation 
to TAT and AuNPs, 356-TAT-AuNPs (1 μmol/kg) exhibited 
remarkable potency with a tumor growth inhibition rate of 
64.1% (Figure 8C). That means, with better tumor inhibition, 
the concentration of 356 in 356-TAT-AuNPs group was 
lowed almost 10-times compared with those in 356 group. 
The test sample was well tolerated with no mortality and no 
significant body weight losses (Figure 8). Also, no significant 
changes in water and food. At the same time, the biodistribu-
tion study in animal model (Figure S7) was also explored, 
and the result had shown that AuNPs were cleared from the 
bloodstream rapidly by i.v. by the reticuloendothelial system, 
and mainly accumulated in the tumor, spleen and liver.
Discussion and Conclusion
Recently, the development of AuNPs for the antitumor agent 
delivery has drawn lots of attention from the medical and 
drug research community. AuNPs (size 20 nm) have been 
modified with varied targeting peptides for functionalizing 
nanoparticles with biological membranes penetrating and 
nucleus targeting effects.18 CPPs have drawn great attention 
due to their special ability to regulate uptake of different 
cargos such as drugs, DNA, and siRNA.19–21 The PAD4 is 
overexpressed in a majority of human cancers markedly, 
indicating that PAD4 could be a putative target in cancer 
treatment. Compound 356, a PAD4 inhibitor, activates p53 
target genes to inhibit cancer growth,7,22,23 but the water 
solubility of 356 is rather poor.
For successful chemotherapy, highly efficient targeted 
drug delivery is crucial. In this study, TAT-AuNPs were 
developed as the drug delivery system which could load 
anticancer compoud 356 via interaction with AuNPs mod-
ified by peptide TAT. 356-TAT-AuNPs suppressed the 
growth of HCT-116, MCF-7 and A549 cells significantly, 
among them the cell line HCT-116 was more sensitive to 
356-TAT-AuNPs. Yuzhalin et al reported that the Cit of the 
extracellular matrix (ECM) molecules catalyzing by extra-
cellular PAD4 was an key event in changing colorectal 
cancer cell signaling.6 Unlike the colorectal tumor cells, 
downregulation of PAD4 expression in breast tumor cells 
led to increase of epithelial-to-mesenchymal transition 
markers (Smad4 and p-Smad2),24 while the overexpres-
sion of PAD4 in lung tumor cells inhibited epithelial-to- 
mesenchymal transition through suppression of Elk1.25 
The release of PAD4 of tumor cells is obviously complex. 
PAD4 inhibitors may act on tumor cells through different 
signals, which may be the reason for the relative sensitiv-
ity to HCT-116. Besides, TAT-AuNPs was used to improve 
the cellular uptake. The experimental results showed that 
TAT-AuNPs provided excellent efficacy in delivering 356 
into HCT-116 cells. To explore the targeting effect into 
HCT-116 cells, the HCT-116 xenografted mice model was 
used. And the result of this in vivo bioassay showed that 
the tumor inhibition rate of the treatment of 356-TAT- 
AuNPs was the highest among all the groups.
Figure 8 Effects of AuNPs, 356 and 356-TAT-AuNPs treatment on the tumorigenicity of HCT-116 cells in vivo. (A) The nude mouse body weight was measured every 2 
days. (B) The tumor volumes of the nude mice were measured and calculated once every 2 days. (C) tumor growth inhibition from tumor-bearing mice after received 
different treatments on the 21st day. Data represent the mean ± SD (n =5). **p < 0.01.
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In this work, an effective drug delivery system on the 
basis of peptide TAT modified AuNPs loading PAD4 inhi-
bitor 356 was designed, prepared, and applied to augment 
the anticancer efficacy. This work proved that the 356-TAT 
-AuNPs exhibited about 16.7 nm nano-sized characteris-
tics, improved the activity in cell membrane penetration 
and PAD4 inhibition with a clearly increase in cell uptake 
and induced tumor cell death, thereby, leading to killing 
tumor cells with higher efficacy. The antitumor results 
in vivo indicated that the combination of peptide TAT 
and AuNPs as drug carrier is potent in inhibiting tumor 
growth and could be a powerful strategy for improved 
development of anticancer drug. Taken together, our 
study demonstrates the design of new PAD4 inhibitor- 
nano delivery system TAT-AuNPs exhibited higher effi-
cient drug release and tumor specificity. So the precisely 
designed and prepared nanostructure showed a synergistic 
efficacy for the antitumor drug and thus may solve the 
current problems of using nanosystems in systematic 
administration.
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